Abstract
Pharmacodiagnostics are considered the pathway to what has been termed
"personalized medicine," the use of molecular analysis to achieve optimum
medical outcomes in the management of a patient' s disease or predisposition to
disease. As such, personalized medicine promises to bring about a new standard
of healthcare, with the possiblity to increase profits, speed clinical trials,
achieve better clinical results and satisfy patients. But how can companies
earn revenue in this undertaking? What are the likely challenges for pharma
companies and IVD companies? Will the current eocnomy impact this emerging
market?
This report, Pharmacodiagnostics and Personalized Medicine (Markets,
Challenges, Forecasts and Key Players) presents a realistic look at the
promise and pitfalls of personalized medicine, with important data useful for
business planning and marketing efforts, including:
- Current Market Size for U.S. Pharmacodiagnostics
- Forecasted Likely and ' Best Case' Revenue Projections to 2018.
- An Overview of the Concept, Past Successes and Failures.
- Potential Pitfalls for PM Strategies
- Forecasts for Pharmacodiagnostics in the U.S. Cancer Treatment Markets (by
type.)
- Possible Cardiological and Psychiatric Treatment Markets
- 8 Strategic Conclusions And Implications For Entrants in this Market
- Profiles of Key Players in Pharmacodiagnostics
Personalized Medicine has given the diagnostics field a huge boost in terms of
publicity/public attention, revenue potential, and investment interest. Still
questions exist as to how extensive such testing will be and how soon we will
see its growth in clinical applications. There are many hurdles to be
overcome, but researchers are confident they can be. For a thorough
understanding of the impact that personalized medicine could have on
pharmaceutical and diagnostic companies, this report reviews these important
factors: including the key challenges new entrants need to overcome to
establish a revenue stream, genome costs, the likely ' Shotgun Effect' on
Pharmaceutical product lines, the challenge of overcoming privacy concerns in
the wake of the GINA legislation, competing cultures between diagnostic and
pharmaceutical companies, and other factors. There are numerous companies
participating in this market and the number is growing. As part of its unique
analysis, the following companies are profiled:
- Abbott Diagnostics
- Affymetrix, Inc.
- Agilent
- Althea Technologies
- Curidium Medica, PLC.
- Dako
- Gen Probe
- Genzyme Corporation
- Ipsogen
- Lipomics
- Osmetech
- Perlegen Sciences
- Provista Life Sciences
- Qiagen
- Singulex
- Theranostics Health
- Ventana Medical Systems
| 
View Cart
